Key Highlights

  • Genmab (NASDAQ:GMAB) shares jumped 12% in European trading on October 26, 2026 after a positive update from a late-stage clinical trial, in published market data from the home market.
  • The US-listed American depositary receipt had not been reported at the time of writing, so the move on Nasdaq is not known and may differ because of currency and trading hours.
  • The specific trial, the endpoint and the size of the benefit were not available for this article, so the strength of the data cannot be judged here.
  • A move of 12% in a large biotech shows how much weight investors put on late-stage data, and it can reverse if details of the trial are less favorable than the headline.

What Happened in Europe

Genmab, a biotechnology company based in Denmark, saw its shares rise 12% in European trading on Monday, October 26, 2026 after a positive update from a late-stage trial, according to published market data. A late-stage trial, usually Phase 3, tests a treatment in a large group of patients and is the last major step before regulatory submission. The information available for this article did not name the trial or give the results, such as survival or response rates, so no clinical figure is stated here. Genmab (NASDAQ:GMAB) trades in the United States as an American depositary receipt, and the US move was not available. The company is known for antibody-based cancer medicines and partnerships with larger drug makers.

How the US Shares Relate

An American depositary receipt is a certificate that represents shares of a foreign company and trades on a US exchange in dollars. Its price follows the home market after allowing for currency, so a 12% gain in Europe usually carries over to the US session, but the exact move depends on the exchange rate and on the trading hours when news emerges. If the news came after the European close or before the US open, the US shares could react differently. Biotech investors usually look at the primary endpoint, safety, the comparison group and the timing of regulatory filings. The headline number is often only part of the story, so analysts read the full data once they are published.

Risks and What to Watch

Positive headline results can be followed by declines if full data show safety concerns or a smaller benefit than expected. Late-stage success also does not guarantee approval or commercial sales. Genmab faces competition in cancer treatments and depends on partnerships and royalties. Investors can watch the full data release, presentation at a medical meeting, regulatory submission plans and the US trading session on October 27, 2026. The Federal Reserve decision on October 28 may also affect biotech sentiment. A large one-day gain can invite profit-taking, especially when details of the data are limited. Royalty and milestone income from partners can make revenue uneven from quarter to quarter. Nothing in this article is investment advice.

Where Things Stand

The answer is that Genmab (NASDAQ:GMAB) jumped 12% in Europe because a late-stage trial update was positive, although the trial name and results were not available for this article. Investors are rewarding the news before the full data are public. The US trading session on October 27, 2026 and the full data release are the next catalysts, and details of the data will decide whether the gain lasts.